• Home
  •  / Dermavant Sciences
Dermavant Sciences

Dermavant Sciences

Dermavant Sciences Summary

Company summary

Dermavant Sciences, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics in medical dermatology. The company’s lead product candidate is Tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent topical cream that is in Phase III clinical trials for the treatment of psoriasis and atopic dermatitis. Its product candidates in Phase I clinical trials include Cerdulatinib (DMVT-505), a dual inhibitor of the Janus kinase and spleen tyrosine kinase pathways for the treatment of vitiligo, as well as other inflammatory skin conditions, such as atopic dermatitis; and Oxybutynin/Pilocarpine (DMVT-504), an investigational oral therapy for the treatment of primary focal hyperhidrosis.
Long Beach, CA, US | view all locations
Cybersecurity rating

Key people

  • Todd Zavodnick

    Todd Zavodnick, Chief Executive Officer and Director

    • Frank Torti

      Frank Torti, Chairman

      • David Rubenstein

        David Rubenstein, Chief Scientific Officer

        • Chris Chapman

          Chris Chapman, Chief Commercial Officer

          LocationsView all

          6 locations detected

          • Long Beach, CA HQ

            United States

            3780 Kilroy Airport Way #250

          • Durham, NC

            United States

            359 Blackwell St #240

          • Morrisville, NC

            United States

            3300 Paramount Pkwy #150

          • New York, NY

            United States

            320 W 37th St 5th floor

          • Phoenix, AZ

            United States

            2398 E Camelback Rd #1060

          • Basel, BS


            Viaduktstrasse 8

          Dermavant Sciences Financials

          Summary financials

          Net income (FY, 2019)
          Cash (FY, 2019)

          Footer menu